Venture-Backed Startups

CellChorus develops a visual AI platform called TIMING that performs high-throughput dynamic analysis of single cells, measuring cell activation, killing, and movement over time for biopharmaceutical research. The company serves biopharmaceutical companies and therapy developers seeking to understand cellular function and phenotype.

4 investors

The Cell engineers breakthrough medicines using molecular simulation and artificial intelligence to accelerate drug discovery and development.

1 investor

0 investors

Cellcraft builds Cellcraft IQ, a hardware-agnostic AI operating system for bioreactor automation and optimisation that turns bioreactors into self-optimising systems. It serves bio-manufacturing customers including biopharma, fermentation, cultivated meat, and cell therapy producers, offering advisory recommendations or full automated control.

1 investor

Cellcrypt provides mobile communications software with dual-layer post-quantum encryption for voice calls, messaging, voice notes, and file sharing. It serves enterprises and governments, offering cloud-hosted and self-hosted/air-gapped deployment options with data hosted under Swiss privacy law and GDPR compliance.

1 investor

Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.

1 investor

Celldom builds a live single-cell biology platform that uses microwell arrays in standard culture plate format, automated imaging, incubation, and real-time analysis to measure morphology, phenotypes, secreted proteins, gene expression, and cell-cell interactions across more than 100,000 cells per plate. It serves drug discovery and cell manufacturing/QC workflows in the life sciences and biotech sector.

2 investors

0 investors

Cellebrite provides digital intelligence software used by law enforcement, national security, and defense agencies to access, extract, secure, and manage digital evidence. Its tools help investigators collect data from digital sources and centralize case intelligence to speed up investigations.

2 investors

CELLECT develops nanomaterial-embedded menstrual products (tampons and pads) that non-invasively collect and preserve DNA from menstrual blood for screening of HPV, cervical cancer, and STDs. The collection system is compatible with existing diagnostic assays and targets women seeking an at-home alternative to Pap smears, including underserved communities.

1 investor

Cellectar Biosciences is a clinical-stage oncology company developing targeted cancer therapies using its proprietary PLE (phospholipid ether) delivery platform, which delivers therapeutic payloads directly to cancer cells. It focuses on advanced cancers with high unmet needs, including work related to triple-negative breast cancer.

0 investors

Cellectis is a gene-editing company that uses its TALEN technology to engineer CAR T-cells from healthy donors into "off-the-shelf" allogeneic immunotherapy candidates aimed at treating cancer and potentially other diseases. It develops therapies designed to be broadly available rather than custom-made per patient.

1 investor

Cellective Biotherapy develops regulatory B10 cell-based immunotherapies designed to enhance or inhibit immune responses for treating cancers, autoimmunity, immunodeficiency, and infectious disease. Its pipeline focuses on first-in-class B cell-directed therapies.

0 investors

Cellemedy develops next-generation therapeutic proteins designed to replace conventional antibody treatments in healthcare.

1 investor

Cellens develops a non-invasive, urine-based cancer diagnostics platform (Octosense) that uses nanoscale atomic-force imaging of single-cell biophysical markers combined with machine learning to detect cancer, with early data focused on bladder cancer detection. It applies mechanobiology and label-free cell analysis to cancer screening.

0 investors

Cellera Farma is a Brazilian pharmaceutical company that manages a portfolio of established medical products through partnerships, licensing, distribution, promotion, and proprietary products. It focuses on therapeutic areas including central nervous system, gastroenterology, orthopedics, and pediatrics.

1 investor

0 investors

0 investors

Cellergy develops allogeneic mitochondrial transplantation therapy, producing GMP-grade purified mitochondria from human primary cells for intravenous, repeated administration. Its therapy targets systemic and degenerative conditions such as CNS disorders, muscle degeneration, and aging, and uses a machine-learning model to predict donor/recipient matching.

1 investor

Cellergy Pharma is a biotechnology company developing CAR T cell therapies that target and eliminate IgE-producing cells to treat severe atopic allergic diseases such as severe allergic asthma and severe food allergy. Founded in 2022, it applies CAR T cell technology beyond cancer to immune-system-driven diseases using its patented EMPD and FcεRI chimeric antigen receptors.

1 investor

Celleste Bio develops a cell-based "cocoa technology" combining biotech, agtech, and AI to produce real cocoa ingredients—including cocoa butter and powder—at scale independent of geography and climate. Its products serve as drop-in replacements for conventional cocoa in chocolate manufacturing.

3 investors

Cellestial Health is a preclinical-stage biotech developing therapies for Parkinson's disease, with a lead candidate rooted in astrocytic network biology. The company focuses on drug discovery for neurological disease.

1 investor

Cellevate develops Cellevat3d nanofiber-based microcarriers and cell culture systems for upstream bioprocessing, used in viral vector, viral vaccine, and stem cell production by gene therapy and biopharmaceutical organizations. Founded as a spinout from NanoLund and Prof. Lars Montelius's group, the company focuses on commercializing nanofiber cell culture technology.

1 investor

CellFE develops a microfluidic-based gene editing technology and a benchtop device for research and process development of cell therapies. Its products serve cell therapy researchers and developers, aiming to enable non-viral genome editing that maintains cell viability and scales from discovery to commercial manufacturing.

3 investors